Of Price Targets and Buyout Rumors for OMPI Print E-mail
By M.E.Garza   
Tuesday, 08 May 2012 04:01
After recently announcing that their Q1 2012 sales rose 16% to a record $30.8 million and notching the highest sales quarter in their firm's history, this specialty pharmaceutical company that develops, markets and sells proprietary skin care systems is rumored to be getting attention from some of the leading consumer cosmetic firms in the world.

In early March, we first told our readers about possible buyout offer developments for 
Obagi Medical Products, Inc. (NASDAQ:OMPI). Shares were trading around the $11 mark at the time and have been trading higher since. 

Shortly after our initial report on, we told readers that Cantor Fitzgerald had increased its price target on Obagi to $14 after the company reported stronger than expected Q4 results. The stock ran to a 52-week high of 13.75 and now trades -10.91 % below that mark.

Within the last few days, the Cantor analysts put out another note to his firm's clients stating that management "was evasive on the call about solicitations of interest from potential acquirers" but that offline the company's management team indicated that "it cannot comment on discussions with suitors and will only make an announcement if a deal is underway." Cantor noted that the most recent dermatology acquisition of privately held Fougera was at a 3.55x multiple of sales, which, if applied to Obagi, would value the company at $23/share. 

Almost simultaneously, Roth Capital just raised Obagi Medical Products' price target to $16 and Canaccord Genuity maintained a 'Buy' on the company with their price target lowered from $22.50 to $21.00.

Clearly, we also continue to hear offer rumors from reputable sources. As we understand it, the firm is and has been weighing several buy-out offers and one major cosmetics space player may be prepared to offer $20+ per share of the company. There are no guarantees that OMPI will take the offer, of course, but it is obvious that someone thinks this is a business worth snatching at a nice premium.

Shares of Obagi Medical Products traded down 4.82% on their good news last Friday, hitting $12.23. OMPI shares have a 52-week low of $8.61 and a 52-week high of $13.75. The company has a market cap of $228.6 million and a price-to-earnings ratio of 23.80. 

Obagi Medical Products sells topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. As far as risk is concerned here, we point to a March note to investors from Cantor Fitzgerald in which they said the firm had two important positive developments: (1) Obagi had resolved its TX dispute and could reinstate HQ sales in the state. They expected a gradual ramp as TX physicians work down existing arbutin (non-HQ) inventories and begin stocking HQ products. Second, the company expects to launch its e-pharmacy in 3Q:12, and management believes that the initiative will result in a 5-year CAGR of 15-20%. 

"Management believes that it can recoup its ~$11M initial investment within 12 months and thinks that the site will require approximately $2-3M in incremental costs to the business, which is viewed as a low-risk investment," wrote Cantor's analyst.

On the flip side,  Elliot Wilbur of  Needham & Company recenty wrote that, "OMPI kicked off its 2012 financials with the largest positive revenue surprise vs. consensus in over two years, even more impressive considering the company derived essentially no benefit from new physician account additions and only a modest contribution from new product introductions in the period. Despite the strong start, management stuck to its guns, reiterating prior year revenue guidance though with resumption of shipments into the Texas market (~8% of historical sales) just yesterday, we suspect top-line trends will at least track toward the higher end of current guidance range." 

For now, Needham  maintains a 'Hold' on Obagi.

Here is a look at the score card for  Obagi Medical Products' analysts:


Disclosure: None

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus